AACR 2024 – a first look at Astra’s ATM inhibitor
One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.
AACR 2024 – Astra plays up PARP1 inhibition
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.
Astra goes early in small cell
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
Astra’s radiopharma Fusion
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
